In high-dose amoxicillin tablet production, the trihydrate form is dispensed on a corrected potency basis because the compendial water content is 11.5–14.5% w/w and only the anhydrous amoxicillin entity contributes to assay. Where the manufacturer selects high-shear wet granulation for a 500 mg tablet, a 300–600 L bowl is charged with amoxicillin trihydrate, microcrystalline cellulose, crospovidone 2–4% w/w, and colloidal silicon dioxide 0.5–1.0% w/w. Aqueous povidone K30 solution 3–5% w/w as dry binder is sprayed during impeller and chopper operation. The endpoint is controlled by main impeller power draw and torque rather than by fixed water volume, because the trihydrate particle size and water content shift the wet mass rheology. Wet massing continues until the granule moisture reaches 8–12% w/w before discharge through a conical mill with 6–10 mm screen. Drying in a fluid-bed dryer is conducted with inlet air 40–60 °C and product temperature not exceeding 45 °C; loss on drying is monitored by USP <731>. After drying, the granules are lubricated with magnesium stearate 0.5–1.0% w/w for 3–5 min and compressed on a rotary tablet press equipped with a pre-compression station. Typical main compression force for a 500 mg tablet falls in the range 12–22 kN, but the specific force-displacement profile is press-specific and published transferable data for this configuration is limited. Tablets are film-coated with an HPMC-based system to 2–3% weight gain. The coated tablets must meet USP <711> dissolution using water, 900 mL, paddle at 75 rpm, with a Q value of 80% dissolved at 30 min. Uniformity of dosage units is assessed by USP <905>; if the active is at least 25% of tablet weight and at least 25 mg per unit, weight variation may apply, but content uniformity remains mandatory for low-dose pediatric strengths. Residual solvent and elemental impurity profiles are controlled against ICH Q3C and ICH Q3D.

Because amoxicillin trihydrate exhibits poor flow and low bulk density, high-speed capsule filling on tamping-pin machines is rarely run with unlubricated powder alone. A dry granulation step is often inserted to increase bulk density and to stabilize fill weight variation on continuous capsule fillers. The API is screened through a 0.8–1.0 mm sieve, blended with microcrystalline cellulose and crospovidone, and compacted in a roller compactor with roll pressure 20–50 kN/cm; the ribbons are milled through 1.0–1.5 mm mesh. The resulting granules are lubricated with 0.5% w/w magnesium stearate and filled into size 0 or 1 hard gelatin or HPMC capsules to a target net fill of 250 mg or 500 mg amoxicillin on the anhydrous basis. Tamping-pin stations are set at 10–16 mm compression depth depending on powder bed column length, and the fill weight is maintained by automatic feedback on a Bosch GKF or MG2 encapsulator. Capsule specifications include USP <711> dissolution with Q = 80% at 30 min, USP <905> uniformity, and moisture limit by USP <921>. Because the trihydrate can liberate water at elevated temperature, capsule packaging includes a desiccant and the bulk intermediate is not stored above 25 °C for extended periods. Excipient compatibility is limited by the beta-lactam ring; strongly alkaline fillers should be avoided because amoxicillin degrades under alkaline hydrolysis.

Dry suspension granulation for amoxicillin oral liquid dosage differs from tablet granulation primarily in the need for rapid dispersion and acceptable palatability after reconstitution. Amoxicillin trihydrate is dry-blended with sucrose or sorbitol, xanthan gum 0.2–0.5% w/w, sodium citrate dihydrate, colloidal silicon dioxide, and flavoring in a low-shear ribbon blender. The initial powder is sieved through 0.8 mm mesh to break agglomerates and then blended for a time established by content uniformity sampling, because segregation in low-density sweetener matrices is a known batch failure mode. The blend is filled into amber HDPE bottles with a desiccant closure; fill weight is adjusted to deliver 125 mg/5 mL, 200 mg/5 mL, 250 mg/5 mL, or 400 mg/5 mL after reconstitution, depending on the licensed strength. The dry powder must pass USP <905> uniformity of dosage units and maintain potency under accelerated storage, with water activity monitored to prevent xanthan gum hydration and microbial growth. At the point of use, potable water is added to the fill line and the bottle is shaken; the vehicle is buffered with citrate to maintain a pH range of 5.0–6.5 after reconstitution, minimizing alkaline hydrolysis of the beta-lactam ring. The reconstituted suspension is typically assigned a 7–14 day discard period when stored at 2–8 °C; the exact in-use period is product-specific and must be supported by preservative-free physical and chemical stability data. Settling rate and redispersibility are controlled by the xanthan gum network; very low yield stress can cause dose non-uniformity, while excessively high yield stress impedes pouring from a measuring spoon or dosing syringe.

What Limits Direct Filling and Sterility Assurance in Amoxicillin Sodium Injection?

Sterile amoxicillin sodium processing for an injectable finished product is segregated from oral dosage manufacturing because the sodium salt is hygroscopic and the beta-lactam nucleus cannot withstand terminal steam sterilization without significant degradation. The route of manufacture is aseptic processing: sterile amoxicillin sodium is crystallized, washed with an appropriate solvent, dried under controlled vacuum, and milled to a particle size suitable for rapid reconstitution. The powder is filled into depyrogenated Type I borosilicate glass vials under Grade A laminar airflow within a RABS or isolator; fill targets include 250 mg, 500 mg, 1 g, and 2 g amoxicillin content as the anhydrous free acid equivalent. Each container is closed with a bromobutyl rubber stopper and sealed with an aluminum flip-off cap. Grade A laminar-air supply must maintain ISO 5 airborne particulate limits of 3,520 particles/m³ at ≥0.5 µm and 20 particles/m³ at ≥5 µm per ISO 14644-1 and EU GMP Annex 1. Because the product is preservative-free and administered by intramuscular or intravenous route, the batch must meet USP <71> sterility, USP <85> bacterial endotoxins, and USP <788> particulate matter for injections. Container closure integrity is verified under USP <1207> conditions; fill-line speed and sterile hold time are established through media fills and closure integrity validation. The reconstituted solution is prepared with water for injection to a concentration appropriate for the route; intramuscular administration typically uses a higher concentration than intravenous infusion. Chemical stability in solution is limited by beta-lactam hydrolysis, and the degradation rate increases with alkaline pH and elevated temperature. Therefore, reconstituted solutions are used promptly, and diluted intravenous infusions are prepared in 0.9% sodium chloride injection rather than strongly alkaline solutions. Published data for extended admixture storage in multiple infusion fluids is limited; facility temperature and time limits must be confirmed with product-specific stability studies. No preservative is present, so any unused portion is discarded after single use.

Amoxicillin–Clavulanate Potassium Co-Granulation Constraints

Fixed-dose amoxicillin/clavulanate products impose a processing conflict: amoxicillin trihydrate requires a wet granulation step to achieve flow and compression hardness, whereas potassium clavulanate is highly moisture-sensitive and degrades rapidly above 30–40% relative humidity and in the presence of free water. For this reason, the two actives are usually granulated separately and blended immediately before compression, or potassium clavulanate is protected by non-aqueous granulation or roller compaction. Ratios in commercial oral solids are standardized around beta-lactamase inhibitor exposure; the 2:1, 4:1, and 7:1 amoxicillin-to-clavulanic acid ratios correspond to 250/125 mg, 500/125 mg, and 875/125 mg tablet strengths based on clavulanic acid content. The co-blend is compressed with a desiccant-lined transfer system and controlled room humidity below 30%; the tablets are film-coated with a moisture-barrier coating of 2–3% weight gain to reduce clavulanate hydrolysis during shelf storage. Dissolution is run by USP <711> for both moieties, with separate analytical quantification because clavulanate potassium has different UV absorption and retention behavior than amoxicillin trihydrate. Batch release includes assay, related substances, water content, and residual solvents. Packaging is typically aluminum/PVC blister with desiccant; bulk containers are not recommended because repeated opening exposes the co-formulated product to ambient moisture.

Dispersible amoxicillin tablets represent a distinct oral solid category because the finished dosage form must disintegrate in a small volume of potable water before administration and still meet dissolution and content uniformity requirements. The formulation uses crospovidone 2–5% w/w and sodium starch glycolate 2–4% w/w as dual disintegrants, microcrystalline cellulose as a diluent, and a sweetener/flavor blend to mask amoxicillin’s bitter taste. The compression profile is adjusted downward compared with film-coated tablets to preserve rapid water uptake: hardness is often controlled in the range 40–70 N, because higher hardness delays disintegration and lower hardness increases edge chipping and friability. Disintegration testing is conducted per USP <701>; the tablet must break down into particles that pass through a sieve screen and form a suspension that can be swallowed by pediatric patients. Dissolution testing uses the same amoxicillin oral solid Q value of 80% at 30 min in 900 mL water with paddle at 75 rpm, but the product is also checked for dispersion uniformity after 60 s of gentle stirring in a small volume of water, because this is the actual patient-use condition. The bulk blend is not subjected to high-shear wet granulation if the target particle size and disintegrant distribution can be achieved by direct compression; when direct compression produces unacceptable segregation, a short low-shear dry granulation or roller compaction step is used. The finished tablets are packaged in aluminum strip or blister with desiccant, and the label states the number of dosing units to be dispersed in 5–10 mL of water immediately before administration.